Atossa to Present at the Sidoti Small-Cap Investor Conference
Get Alerts ATOS Hot Sheet
Join SI Premium – FREE
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
To register and view a live webcast of the presentation, please visit the event's website at: https://sidoti.zoom.us/webinar/register/WN_MB9PZN5rTjeg5vMpcE82Gg
Following the conference, a recording of the webcast will be made available on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com/
About Atossa TherapeuticsAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:Eric Van ZantenVP, Investor and Public Relations610-529-6219[email protected]
Source: Atossa Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DevOpser Stores Turns a Single Sentence Into a Digital Storefront That Gets You Paid
- Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Only 31% of Organizations Have Visibility into AI Software as Spend Surges, Flexera 2026 State of ITAM Report Reveals
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Sidoti & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share